Views & Analysis Tunnah’s musings: Rare diseases hold key to future of drug d... The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.
Views & Analysis Rethinking rare diseases: treat the whole patient CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.